Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Ardent Health's 2025 Net Income Drops $69.6M

Ardent Health’s 2025 net income fell to $230.1 million from $299.7 million in 2024, a decline of $69.6 million. Adjusted EBITDA also moved lower, dropping to $447.3 million from $498.5 million, down $51.2 million year over year.

The company’s top-line reconciliation showed several offsetting changes. Income tax expense eased to $56.2 million from $63.4 million, while interest expense declined to $55.2 million from $65.6 million. Depreciation and amortization increased to $155.7 million from $146.3 million.

Noncontrolling interest earnings widened slightly to $94.3 million from $89.4 million, reducing the adjusted figure by a larger amount. The biggest upward adjustment came from equity-based compensation, which more than doubled to $39.3 million from $18.0 million. Epic implementation costs rose to $4.8 million from $3.2 million, and restructuring, exit and acquisition-related costs edged up to $13.3 million from $12.8 million.

Cybersecurity incident recoveries, net, were $22.7 million in 2025, compared with $21.5 million in 2024. Loss on extinguishment and modification of debt increased to $7.3 million from $3.4 million, and certain legal matters and related costs declined to $0.9 million from $2.0 million.

For the fourth quarter, net income was $74.3 million, and Adjusted EBITDAR was $175.7 million. Full-year Adjusted EBITDAR reached $611.6 million, up from the year’s net income by $381.4 million after adding back $164.3 million of rent expense payable to REITs. The quarterly rent expense payable to REITs was $41.8 million, including $38.9 million tied to Ventas leases and $2.9 million tied to the MPT lease. The market has reacted to these announcements by moving the company's shares 1.39% to a price of $10.91. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS